Search for a trial

A Long-term Extension Study to Evaluate the Safety and Tolerability of TAK-861 in Participants With Selected Central Hypersomnia Conditions

This study has been transitioned to CTIS with ID 2023-508462-15-00 check the CTIS register for the current data. To evaluate the long-term safety and tolerability of TAK-861.

Nivolumab during active surveillance after neoadjuvant chemoradiation for esophageal cancer: SANO-3 study

This study has been transitioned to CTIS with ID 2024-513635-24-00 check the CTIS register for the current data. The aim of the study is to investigate the effectiveness and safety of the new drug nivolumab for the treatment of esophageal cancer. In…

Immune profiling of stage III non-small cell lung cancer patients treated with concurrent chemoradiation and adjuvant durvalumab: A prospective observational phase II trial

Primary Objective: To identify immune changes between baseline, one week of radiotherapy, end of radiotherapy and three months of durvalumab- Identification of differentially expressed proteins at all time points- Identification of differentially…

EMDR Flash Forward as an intervention on the mental images of worst case scenarios in paranoid delusions

Primary Objective: Investigate whether EMDR Flash Forward is an effective intervention to process the mental images of worst case scenarios that occur in paranoid delusions, in order to decreases the preoccupation with the delusion.Secondary…

A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, formerly PT2977) Monotherapy in Participants with Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), or von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2α related Genetic Alterations

This study has been transitioned to CTIS with ID 2023-504853-11-00 check the CTIS register for the current data. To evaluate the ORR of belzutifan per RECIST 1.1 by blinded independent central review (BICR).

An Open-Label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Bempedoic
Acid in Pediatric Patients (6 to 17 Years of Age) with Heterozygous Familial Hypercholesterolemia

This study has been transitioned to CTIS with ID 2024-515864-30-00 check the CTIS register for the current data. Primary Objectives:• To assess the pharmacokinetics (PK) of bempedoic acid (ETC-1002 and ESP15228) in pediatric patients (6 to 17 years…

A Phase I/II, multi-center, open label study of DYP688 in patients with MUM and other GNAQ/11 mutant melanomas (study CDYP688A12101)

This study has been transitioned to CTIS with ID 2023-509451-14-00 check the CTIS register for the current data. Primary:Phase I: • To characterize the safety and tolerability and to identify the maximum tolerated dose (MTD) and/or recommended dose…

CD8 T cell imaging by positron emission tomography with 89Zr-Df-IAB22M2C in giant cell arteritis and rheumatoid arthritis: a pilot study

Primary Objective: to evaluate arterial or synovial 89Zr-Df-crefmirlimab uptake on PET/CT in patients with GCA or RASecondary objectives are:1. Assessment of the relationship between 89Zr-Df-crefmirlimab uptake and the presence of CD8 T cells in…

PNOC022: A Combination Therapy Trial using an Adaptive Platform Design for Children and Young Adults with Diffuse Midline Gliomas (DMGs) including Diffuse Intrinsic Pontine Gliomas (DIPGs) at Initial Diagnosis, Post-Radiation Therapy and at Time of Progression

This study has been transitioned to CTIS with ID 2023-507598-16-00 check the CTIS register for the current data. Primary objectives:Cohorts 1 and 2Maintenance Arm(s) Combinations:-To assess efficacy of combination therapy with ONC201 and novel agent…

Intraperitoneal irinotecan with concomitant FOLFOX and bevacizumab for patients with unresectable colorectal peritoneal metastases - a phase II study

This study has been transitioned to CTIS with ID 2024-517152-34-00 check the CTIS register for the current data. The primary objectives are to explore the overall survival for the addition of intraperitoneal irinotecan (75 mg) to palliative systemic…

Phase 2 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sotatercept (MK-7962) in Children from 1 to Less Than 18 Years of Age With PAH on Standard of Care

This study has been transitioned to CTIS with ID 2023-504861-22-00 check the CTIS register for the current data. This study will assess the safety and tolerability of sotatercept in pediatric participants with PAH WHO Group 1 who receive PAH…

A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants With RCC (KEYMAKER-U03): Substudy 03B

This study has been transitioned to CTIS with ID 2023-506839-15-00 check the CTIS register for the current data. Primary objectives:# Safety Lead-in Phase: To assess the safety and tolerability, and to establish an RP2D if applicable, of treatment…

A Phase II, Multi-center, Open-Label Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of R3R01 in Alport Syndrome Patients with Uncontrolled Proteinuria on ACE/ARB Inhibition and in Patients with Primary Steroid-Resistant Focal Segmental Glomerulosclerosis.

This study has been transitioned to CTIS with ID 2024-512964-73-00 check the CTIS register for the current data. The overall objective is to investigate the safety, tolerability, efficacy and pharmacokinetics of R3R01 administered daily for 3 months…

A Phase 2, Single-Arm, Open-Label Study with Dostarlimab Monotherapy in Participants with Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer

This study has been transitioned to CTIS with ID 2023-509583-22-00 check the CTIS register for the current data. Primary objective:To estimate the efficacy of dostarlimab in participants with Stage II/III (locally advanced) dMMR/MSI-H rectal cancer…